



T: 212.735.3274
deni.li@skadden.com

Education

J.D., Georgetown University
Law Center, 2013

LL.B., Peking University, 2009

Bar Admissions

New York

Deni Li represents U.S. and international corporate clients and investment banks in a variety of capital markets transactions, including initial public offerings and secondary equity offerings, public and private offerings of investment-grade and high-yield debt, spin-offs and other strategic corporate transactions. Ms. Li has significant experience representing foreign private issuers across a wide range of industries, including advising:

- Royal Caribbean Cruises Ltd. on its Rule 144A/Reg S \$3.32 billion senior secured notes offering and \$1 billion senior guaranteed notes offering, registered \$500 million common stock offering and \$1 billion at-the-market offering, and several tranches of senior notes and convertible notes offerings totaling \$6 billion;
- Alcon, Inc. on its Rule 144A/Reg S \$2.75 billion senior notes offerings;
- Party City Holdco on its \$2 billion debt restructuring and \$750 million senior secured notes offering;
- Sea Limited on its Rule 144A/Reg S \$1 billion convertible notes offering and registered \$2.6 billion offering of American depository shares;
- Nano-X Imaging Ltd on its \$200 million IPO on the Nasdaq and \$193 million secondary offering;
- Beyond Spring, Inc. on its IPO on the Nasdaq and concurrent private placement, as well as multiple follow-on and at-the-market offerings;
- Drawbridge Special Opportunities Fund, the credit business of Fortress Investment Group, on its 4(a)(2) private placement of \$160 million senior notes and its Rule 144A \$400 million senior note offering and tender offer;
- the Washington Corporations on its Rule 144A/Reg S \$550 million second lien secured notes offering in connection with its acquisition of Dominion Diamond Corporation;
- the initial purchasers on the Rule 144A/Reg S high-yield offerings of dollar- and euro-denominated senior notes of Avis Budget Group;
- Meituan Dianping on its \$4.2 billion IPO on the Hong Kong Stock Exchange and BeiGene Ltd. on its \$903 million IPO on the Hong Kong Stock Exchange (the first dual primary listing of a Nasdaq-listed biotechnology company);
- various SPAC IPOs totaling \$1 billion; and
- various additional corporate clients, including SunEdison, Fortress Investment Group, Green Bancorp, Inc., Qatar Investment Authority and Aflac Ventures, on a variety of capital markets and/or investment transactions.